Completed Studies
Please find a list of studies the PRCSG has completed below.
| Title | Years |
|---|---|
| Secukinumab Safety and Efficacy in JPsA and ERA | 2017-2021 |
| Efficacy, Safety and Tolerability of Tofacitinib For Treatment of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) In Children And Adolescent Subjects | 2016 - 2019 |
| A study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab | 2013 - 2019 |
| A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | 2013 - 2018 |
| A Phase Ib, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration to patients with systemic juvenile idiopathic arthritis | 2013 - 2017 |
| A Phase Ib, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration to patients with polyarticular-course juvenile idiopathic arthritis | 2013 - 2017 |
| A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) | 2013 - 2017 |
| An Open-label Multiple Dose Study to Evaluate he Pharmacokinetics, Safety and Tolerability of Cp-690,550 in Pediatric Patients from 2 to less than 18 Years of Age with Juvenile Idiopathic Arthritis (JIA) | 2013 - 2016 |
| A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less than 2 Years Old with Active Systemic Juvenile Idiopathic Arthritis (SJIA) | 2012 - 2016 |
| A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/200 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, with Juvenile Idiopathic Arthritis (JIA) | 2012 - 2015 |
| Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Validation Study | 2011 - 2012 |
| A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFa Antidoby, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis (JIA) Despite Methotrexate Therapy | 2010 - 2014 |
| An open label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation | 2009 - 2017 |
| An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305; and response characterization study in cankinumab treatment-naïve patients with active SJIA with and without fever | 2009 - 2014 |
| A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis | 2009 - 2013 |
| A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations | 2009 - 2012 |
| SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs | 2009 - 2012 |
| A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation | 2009 - 2011 |
| Compassionate Use Study of Adalimumab in Children 2 <4 Years Old or Age 4 and Above Weighing Less than 15 kg with Active Juvenile Idiopathic Arthritis (JIA) | 2009 - 2011 |
| A 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthritis (sJIA); with a 92-week sing arm open-label extension to examine the long term use of tocilizumab, followed by a 3 year open label continuation of the study to examine the long term use of tocilizumab | 2008 - 2014 |
| A Pilot, Multi-Center, Randomized, Double Blind, Placebo Controlled, Ascending Dose, Safety, Tolerability and Preiminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA) | 2005 - 2008 |
| BMS-188667 in Children and Adolescents with Juvenile Rheumatoid Arthritis | 2004 - 2011 |
| Clinical Protocol for a Randomized, Double-blind Multi-center, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients with JRA | 2002 - 2004 |
| Efficacy and Safety of Leflunomide versus Methorexate Comparison in Patients with Juvenile Rheumatoid Arthritis (JRA) | 2002 - 2003 |
| A 52-Week, Open Label, Active Comparator Controlled Extension to a 12-Week Trial of Rofecoxib in Juvenile Rheumatoid Arthritis Patients | 2001 - 2006 |
| A Randomized, Double-blind Trial of Anti-TNF alpha Chimeric Monoclonal Antibody (INFLIXIMAB) in Combination with Methotrexate for the Treatment of Patients with Polyarticular JRA | 2001 - 2003 |
| Phase IV Registry of etanercept (Enbrel) in children with Juvenile Rheumatoid Arthritis. Data submitted for publication | 2000 - 2008 |
| Development and Validation of Core Sets of Outcome Measures and Definitions of Improvement for Juvenile Dermatomyositis and Juvenile Systemic Lupus Erythematosus | 2000 - 2003 |
| A Randomized, Multi-center, Blinded, Placebo-controlled Study with an Open Label Run-in Period to Evaluate the Efficacy, Safety & Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHUlL-Ira (Anakinra) in Polyarticular Course JRA | 2000 - 2003 |
| A Companion Extension Study to Evaluate the Long-term Safety of Daily, Single, Subcutaneous injections of r-metHulL-1ra (Anakinra) in Subjects with Polyarticular Course JRA who participated in IL-1ra (Protocol 990758) | 2000 - 2003 |
| Neoral in Polyarticular Course JRA: Post-marketing Surveillance | 1999 - 2002 |
| An Open, Oral Dose Study to Evaluate the Steady State Plasma Concentration Profile of MK-0966, Followed by a 12-Week, Double-blind, Active-comparator-controlled Extension, in Late- and Post-pubertal Adolescents With Juvenile Rheumatoid Arthritis | 1999 - 2000 |
| Therapeutic Exploratory Trial of Cosamin DS in JRA | 1999 - 2000 |
| Parenteral Methotrexate in Medium versus High-dosed for the Treatment of Idiopathic Arthritis of Childhood | 1998 - 2000 |
| Phase I Trial - Leflunomide in Poly course JRA | 1998 - 1999 |
| Open-label Treatment with TNFR:Fc in JRA | 1997 - 2001 |
| Safety, Population PK and Efficacy of Recombinant Human Tumor Necrosis Factor Receptor (P75) Fc Fusion Protein (TNFR:Fc) in Children with JRA | 1997 - 1998 |
| A Double-blind, Randomized, Vehicle-controlled, Parallel Group Multi-center Pilot Study Evaluating the Safety and Efficacy of Civamide Cream, 0.075% in Children with Pauciarticular Juvenile Rheumatoid Arthritis Disease of the Knee | 1995 - 1996 |
| Phase I/II study of DAB389IL-2 Fusion Toxin in Patients with Severe Polyarticular Juvenile Rheumatoid Arthritis | 1994 - 1996 |
| Intravenous Gammaglobulin (IVEEGAM) in Polyarticular Juvenile Rheumatoid Arthritis | 1992 - 1996 |
| Intravenous Gammaglobulin in Severe Polyarticular JRA Patients | 1990 - 1992 |